This study was undertaken to investigate real-world effectiveness of coronavirus disease 2019 (COVID-19) vaccination on subsequent infection in patients with inflammatory bowel disease (IBD) with diverse exposure to immunosuppressive medications. Researchers conducted a retrospective cohort study of individuals in the Veterans Health Administration with IBD diagnosed before December 18, 2020, the start date of the Veterans Health Administration patient vaccination program. They applied inverse probability weighting and Cox’s regression with vaccination status as a time-updating exposure and computed vaccine effectiveness from incidence rates. The study included 14,697 individuals, 7321 of whom received at least 1 vaccine dose (45.2% Pfizer, 54.8% Moderna). The findings suggest that full vaccination (> 7 days after the second dose) against SARS-CoV-2 infection has an ∼80.4% effectiveness in a broad IBD cohort with diverse exposure to immunosuppressive medications. These outcomes may serve to elevate patient and provider willingness to pursue vaccination in these settings.
Read the full article on Gastroenterology